Pyxis Oncology (PYXS) Research & Development (2020 - 2025)

Pyxis Oncology (PYXS) has 6 years of Research & Development data on file, last reported at $21.7 million in Q4 2025.

• Research & Development for Q4 2025 came in at $21.7 million, up 54.81% year-over-year; the trailing twelve-month figure through Dec 2025 was $73.7 million (up 25.45% YoY), and the FY2025 annual result was $73.7 million, up 25.45% from the prior year.
• Research & Development climbed to $21.7 million in Q4 2025 per PYXS's latest filing, from $17.8 million in the prior quarter.
• Over five years, Research & Development peaked at $32.8 million in Q1 2021 and troughed at $3.2 million in Q2 2021.
• A 5-year average of $16.0 million and a median of $15.9 million in 2023 frame the typical range for Research & Development.
• The sharpest annual moves came in 2022 and 2023: Research & Development jumped 435.73% in 2022, then tumbled 61.12% in 2023.
• A 5-year view of Research & Development shows it stood at $7.2 million in 2021, then soared by 313.15% to $29.9 million in 2022, then plunged by 61.12% to $11.6 million in 2023, then advanced by 20.82% to $14.0 million in 2024, then surged by 54.81% to $21.7 million in 2025.
• Business Quant data shows PYXS's Research & Development at $21.7 million in Q4 2025, $17.8 million in Q3 2025, and $17.1 million in Q2 2025.